Overview

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
UCB Pharma
Treatments:
N 0437
Rotigotine
Criteria
Inclusion Criteria:

- Subjects who have completed six months of maintenance treatment in the SP513
double-blind trial

Exclusion Criteria:

- Subjects who had an ongoing serious adverse event from SP513 double-blind trial that
was assessed as related to study medication